Astec LifeSciences Limited (ASTEC) - Net Assets
Based on the latest financial reports, Astec LifeSciences Limited (ASTEC) has net assets worth Rs4.14 Billion INR (≈ $44.80 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs8.83 Billion ≈ $95.53 Million USD) and total liabilities (Rs4.69 Billion ≈ $50.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Astec LifeSciences Limited to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs4.14 Billion |
| % of Total Assets | 46.9% |
| Annual Growth Rate | 14.66% |
| 5-Year Change | -24.02% |
| 10-Year Change | 100.98% |
| Growth Volatility | 45.15 |
Astec LifeSciences Limited - Net Assets Trend (2008–2025)
This chart illustrates how Astec LifeSciences Limited's net assets have evolved over time, based on quarterly financial data. Also explore ASTEC asset base for the complete picture of this company's asset base.
Annual Net Assets for Astec LifeSciences Limited (2008–2025)
The table below shows the annual net assets of Astec LifeSciences Limited from 2008 to 2025. For live valuation and market cap data, see ASTEC market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.35 Billion ≈ $25.42 Million |
-36.40% |
| 2024-03-31 | Rs3.70 Billion ≈ $39.96 Million |
-11.93% |
| 2023-03-31 | Rs4.20 Billion ≈ $45.37 Million |
+5.77% |
| 2022-03-31 | Rs3.97 Billion ≈ $42.90 Million |
+28.24% |
| 2021-03-31 | Rs3.09 Billion ≈ $33.45 Million |
+25.28% |
| 2020-03-31 | Rs2.47 Billion ≈ $26.70 Million |
+21.74% |
| 2019-03-31 | Rs2.03 Billion ≈ $21.93 Million |
+19.34% |
| 2018-03-31 | Rs1.70 Billion ≈ $18.38 Million |
+22.99% |
| 2017-03-31 | Rs1.38 Billion ≈ $14.94 Million |
+18.16% |
| 2016-03-31 | Rs1.17 Billion ≈ $12.65 Million |
-13.63% |
| 2015-03-31 | Rs1.35 Billion ≈ $14.64 Million |
+19.25% |
| 2014-03-31 | Rs1.14 Billion ≈ $12.28 Million |
+7.24% |
| 2013-03-31 | Rs1.06 Billion ≈ $11.45 Million |
+7.26% |
| 2012-03-31 | Rs987.06 Million ≈ $10.67 Million |
+1.73% |
| 2011-03-31 | Rs970.25 Million ≈ $10.49 Million |
+4.21% |
| 2010-03-31 | Rs931.08 Million ≈ $10.07 Million |
+186.27% |
| 2009-03-31 | Rs325.25 Million ≈ $3.52 Million |
+41.56% |
| 2008-03-31 | Rs229.75 Million ≈ $2.48 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Astec LifeSciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1744.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs1.41 Billion | 60.12% |
| Common Stock | Rs196.11 Million | 8.35% |
| Other Comprehensive Income | Rs2.15 Billion | 91.65% |
| Total Equity | Rs2.35 Billion | 100.00% |
Astec LifeSciences Limited Competitors by Market Cap
The table below lists competitors of Astec LifeSciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seronics Co. Ltd
KQ:042600
|
$167.44 Million |
|
Sea Sonic Electronics Co Ltd
TWO:6203
|
$167.45 Million |
|
Mendelson Infrastructures and Industries Ltd
TA:MNIN
|
$167.51 Million |
|
CareRx Corp
TO:CRRX
|
$167.61 Million |
|
Waton Financial Limited Ordinary Shares
NASDAQ:WTF
|
$167.38 Million |
|
Genexine Inc
KQ:095700
|
$167.36 Million |
|
STLLR Gold Inc.
TO:STLR
|
$167.34 Million |
|
Premia S.A.
AT:PREMIA
|
$167.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Astec LifeSciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,692,871,000 to 2,347,452,000, a change of -1,345,419,000 (-36.4%).
- Net loss of 1,347,524,000 reduced equity.
- Share repurchases of 23,000 reduced equity.
- New share issuances of 23,000 increased equity.
- Other comprehensive income increased equity by 2,147,445,000.
- Other factors decreased equity by 2,145,340,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs-1.35 Billion | -57.4% |
| Share Repurchases | Rs23.00K | -0.0% |
| Share Issuances | Rs23.00K | +0.0% |
| Other Comprehensive Income | Rs2.15 Billion | +91.48% |
| Other Changes | Rs-2.15 Billion | -91.39% |
| Total Change | Rs- | -36.43% |
Book Value vs Market Value Analysis
This analysis compares Astec LifeSciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 28.79x to 5.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-03-31 | Rs24.13 | Rs694.70 | x |
| 2009-03-31 | Rs34.26 | Rs694.70 | x |
| 2010-03-31 | Rs77.15 | Rs694.70 | x |
| 2011-03-31 | Rs57.18 | Rs694.70 | x |
| 2012-03-31 | Rs58.20 | Rs694.70 | x |
| 2013-03-31 | Rs60.94 | Rs694.70 | x |
| 2014-03-31 | Rs62.01 | Rs694.70 | x |
| 2015-03-31 | Rs72.45 | Rs694.70 | x |
| 2016-03-31 | Rs59.86 | Rs694.70 | x |
| 2017-03-31 | Rs70.64 | Rs694.70 | x |
| 2018-03-31 | Rs86.70 | Rs694.70 | x |
| 2019-03-31 | Rs103.44 | Rs694.70 | x |
| 2020-03-31 | Rs125.97 | Rs694.70 | x |
| 2021-03-31 | Rs157.83 | Rs694.70 | x |
| 2022-03-31 | Rs202.30 | Rs694.70 | x |
| 2023-03-31 | Rs213.89 | Rs694.70 | x |
| 2024-03-31 | Rs188.30 | Rs694.70 | x |
| 2025-03-31 | Rs119.69 | Rs694.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Astec LifeSciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -35.34%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 3.75x
- Recent ROE (-57.40%) is below the historical average (8.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 34.92% | 14.40% | 0.70x | 3.45x | Rs56.70 Million |
| 2009 | 32.12% | 12.29% | 0.86x | 3.02x | Rs71.45 Million |
| 2010 | 14.23% | 11.80% | 0.73x | 1.66x | Rs39.24 Million |
| 2011 | 5.06% | 4.48% | 0.61x | 1.85x | Rs-47.81 Million |
| 2012 | 1.39% | 1.21% | 0.49x | 2.35x | Rs-84.87 Million |
| 2013 | 5.63% | 3.41% | 0.67x | 2.47x | Rs-46.23 Million |
| 2014 | 7.64% | 4.19% | 0.73x | 2.51x | Rs-26.73 Million |
| 2015 | 10.92% | 5.54% | 0.73x | 2.68x | Rs12.42 Million |
| 2016 | -16.40% | -7.39% | 0.70x | 3.18x | Rs-308.49 Million |
| 2017 | 13.85% | 6.40% | 0.90x | 2.42x | Rs53.16 Million |
| 2018 | 20.57% | 9.66% | 0.87x | 2.44x | Rs179.39 Million |
| 2019 | 17.65% | 8.29% | 0.93x | 2.28x | Rs154.88 Million |
| 2020 | 19.27% | 9.09% | 0.91x | 2.32x | Rs228.55 Million |
| 2021 | 21.04% | 11.72% | 0.82x | 2.19x | Rs341.31 Million |
| 2022 | 22.66% | 13.28% | 0.75x | 2.26x | Rs502.09 Million |
| 2023 | 6.10% | 4.07% | 0.64x | 2.34x | Rs-163.71 Million |
| 2024 | -12.71% | -10.24% | 0.47x | 2.64x | Rs-838.58 Million |
| 2025 | -57.40% | -35.34% | 0.43x | 3.75x | Rs-1.58 Billion |
Industry Comparison
This section compares Astec LifeSciences Limited's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $5,291,729,485
- Average return on equity (ROE) among peers: 15.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Astec LifeSciences Limited (ASTEC) | Rs4.14 Billion | 34.92% | 1.13x | $167.40 Million |
| Agro Phos India Limited (AGROPHOS) | $469.69 Million | 12.41% | 0.80x | $6.93 Million |
| Bayer Cropscience Limited (BAYERCROP) | $25.24 Billion | 25.56% | 0.72x | $2.32 Billion |
| Best Agrolife Limited (BESTAGRO) | $31.27 Million | 2.19% | 4.68x | $68.89 Million |
| Bhagiradha Chemicals & Industries Limited (BHAGCHEM) | $439.63 Million | 21.56% | 0.95x | $371.49 Million |
| Bharat Rasayan Limited (BHARATRAS) | $285.91 Million | 5.42% | 0.41x | $248.90 Million |
| Bohra Industries Limited (BOHRAIND) | $340.42 Million | 12.70% | 2.21x | $2.15 Million |
| Bombay Super Hybrid Seeds Limited (BSHSL) | $15.23 Million | 16.29% | 1.68x | $111.73 Million |
| Chambal Fertilizers & Chemicals Limited (CHAMBLFERT) | $12.85 Billion | 17.46% | 3.55x | $1.90 Billion |
| Coromandel International Limited (COROMANDEL) | $7.96 Billion | 26.41% | 2.41x | $6.32 Billion |
About Astec LifeSciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maiz… Read more